ATE328586T1 - Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslauföffnung in situ gebildet wird - Google Patents

Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslauföffnung in situ gebildet wird

Info

Publication number
ATE328586T1
ATE328586T1 AT96908796T AT96908796T ATE328586T1 AT E328586 T1 ATE328586 T1 AT E328586T1 AT 96908796 T AT96908796 T AT 96908796T AT 96908796 T AT96908796 T AT 96908796T AT E328586 T1 ATE328586 T1 AT E328586T1
Authority
AT
Austria
Prior art keywords
water soluble
medicament
coating layer
controlled release
pharmaceutically acceptable
Prior art date
Application number
AT96908796T
Other languages
English (en)
Inventor
Chih-Ming Chen
Der-Yang Lee
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE328586T1 publication Critical patent/ATE328586T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96908796T 1995-04-28 1996-03-13 Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslauföffnung in situ gebildet wird ATE328586T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/431,404 US5558879A (en) 1995-04-28 1995-04-28 Controlled release formulation for water soluble drugs in which a passageway is formed in situ

Publications (1)

Publication Number Publication Date
ATE328586T1 true ATE328586T1 (de) 2006-06-15

Family

ID=23711795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908796T ATE328586T1 (de) 1995-04-28 1996-03-13 Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslauföffnung in situ gebildet wird

Country Status (11)

Country Link
US (1) US5558879A (de)
EP (1) EP0822809B1 (de)
JP (1) JPH11511115A (de)
CN (1) CN1090017C (de)
AT (1) ATE328586T1 (de)
AU (1) AU695713B2 (de)
CA (1) CA2217226C (de)
DE (1) DE69636223T2 (de)
ES (1) ES2267107T3 (de)
NZ (1) NZ304661A (de)
WO (1) WO1996033700A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
EP0811374A1 (de) * 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
AU721653B2 (en) * 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0951278A2 (de) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Minitablette formulierung zur verzögerte freigabe von cisapride
AU7706598A (en) * 1997-05-30 1998-12-30 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
TW586944B (en) * 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
KR100827254B1 (ko) * 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
OA11740A (en) * 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
KR20130010512A (ko) * 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
WO2003026555A2 (en) * 2001-09-25 2003-04-03 J.B. Chemicals & Pharmaceuticals Ltd. Floating osmotic device for controlled release drug delivery
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20040062804A1 (en) * 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
PL373031A1 (en) * 2002-04-29 2005-08-08 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) * 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
EP1575565B1 (de) 2003-08-08 2010-01-06 Biovail Laboratories International Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
KR100636546B1 (ko) * 2005-02-15 2006-10-19 한국유나이티드제약 주식회사 방출 연장성 펠로디핀과 말레인산 에날라프릴을 함유하는경구 복합 제제의 조성물 및 그의 제조방법
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
ES2459322T3 (es) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH)
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
CN105581984A (zh) * 2009-04-09 2016-05-18 阿尔科米斯制药爱尔兰有限公司 药物递送组合物
US20110070305A1 (en) * 2009-09-24 2011-03-24 Alpharx Inc. Sustained release pharmaceutical composition containing mebicar
CA2775890C (en) * 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
US10463611B2 (en) 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
DE102011051653A1 (de) * 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
US9226891B2 (en) 2011-10-28 2016-01-05 Vitalis Llc Anti-flush compositions
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
MX356727B (es) 2012-02-08 2018-06-12 Supernus Pharmaceuticals Inc Formulaciones de liberacion modificada de viloxacina.
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
GB201316857D0 (en) * 2013-09-23 2013-11-06 Buckley Howard Composition for the oral delivery of compounds
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CA2978593A1 (en) * 2015-01-12 2016-07-21 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
US9579289B2 (en) 2015-02-20 2017-02-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
HU205851B (en) * 1989-01-31 1992-07-28 Int Pharma Agentur Systhem of regulated release of the active components and process for producing it
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
DK0707475T3 (da) * 1993-06-14 1997-12-29 Janssen Pharmaceutica Nv Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
AU5251896A (en) 1996-11-18
CA2217226C (en) 2006-05-30
EP0822809A1 (de) 1998-02-11
DE69636223D1 (de) 2006-07-20
ES2267107T3 (es) 2007-03-01
AU695713B2 (en) 1998-08-20
CN1182363A (zh) 1998-05-20
CA2217226A1 (en) 1996-10-31
JPH11511115A (ja) 1999-09-28
DE69636223T2 (de) 2007-04-19
CN1090017C (zh) 2002-09-04
WO1996033700A1 (en) 1996-10-31
NZ304661A (en) 1998-06-26
US5558879A (en) 1996-09-24
EP0822809B1 (de) 2006-06-07
EP0822809A4 (de) 1999-07-07

Similar Documents

Publication Publication Date Title
ATE328586T1 (de) Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslauföffnung in situ gebildet wird
EP0111144B1 (de) Feste Dosierungsformen mit verzögerter Freigabe, die keine einheitliche Verteilung des aktiven Stoffes aufweisen
US4610870A (en) Controlled release formulation
US5736159A (en) Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
EP0835102A4 (de) Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
US5837379A (en) Once daily pharmaceutical tablet having a unitary core
US6500459B1 (en) Controlled onset and sustained release dosage forms and the preparation thereof
AU603904B2 (en) Controlled release formulation
AU639231B2 (en) Sustained release pharmaceutical preparations containing an analgesic and a decongestant
CA2232356A1 (en) Method of producing multi-layer medicaments in solid form for oral or rectal administration
CA2290624A1 (en) Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
JPS62267221A (ja) 新規薬物製剤
ATE246505T1 (de) Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix
ZA975827B (en) Stable medicament with benzimidazole derivatives as an active ingredient for oral administration and method for its production.
US6485748B1 (en) Once daily pharmaceutical tablet having a unitary core
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
CN101371824B (zh) 以甲泼尼龙及其衍生物为活性成分的口腔粘贴片
EP0761209A3 (de) Ranitidinformulierungen mit gesteuerter Freisetzung
JP2003514847A (ja) 第一コートおよび第二コートを含む浸透圧性剤形
CA2223014A1 (en) Controlled release formulation having a preformed passageway
Samy et al. Formulation and evaluation of controlled release ibuprofen tablets

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties